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Few studies have assessed the extent of psychoactive drug con-
sumption in the occupational setting. The trucking sector, in 
particular, is an important cause for concern, since psychoac-
tive substance use has a relevant impact on the drivers’ health 
and safety, increasing the risk of injuries and traffic accidents, 
potentially affecting the general public health as well. A system-
atic review of the literature and meta-analysis was performed in 
order to provide Occupational Health Professionals and policy-
makers with an updated epidemiological perspective regarding 
this important issue. The results showed a prevalence of overall 
drug consumption of 27.6% [95%CI 17.8-40.1], particularly high 
considering illicit CNS-stimulants (amphetamine consumption 
of 21.3% [95%CI 15.7-28.1], and cocaine consumption of 2.2% 
[95%CI 1.2-4.1]). It appears that truck-drivers choose stimulant 
substances as a form of performance enhancing drug, in order 
to increase productivity. However, chronic and high dose con-
sumption has been shown to decrease driving skills, placing these 
professional drivers at risk for health and road safety. Further 
research is required, particularly in Europe, in order to fill the 
knowledge gap and improve the strength of evidence.
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Introduction
Illicit drug and psychoactive substance misuse is an 
important contributor to the global burden of disease. 
According to data presented in the World Drug Review 
2018 published by the United Nations Office on Drugs 
and Crime (UNODC), 5.6% of the global population 
aged 15-64 years has used drugs in the previous year. 
Moreover, medical and non-medical prescription drug 
abuse, especially opioids, is reaching epidemic propor-
tions in many parts of the world [1].
These figures represent an increasing trend over the 
years, especially in developed countries. In its European 
Drug Report 2018, the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) has reported 
an annual prevalence of drug users equal to 7.4%, and 
drug-induced mortality surpassing 5 thousands deaths in 
EU countries [2]. Since working age population makes 
up most of the overall population, substance use among 
workers is of primary interest from an occupational per-
spective. Indeed, it can cause loss of productivity, work-
place injuries, absenteeism and increased illness [3]. 
Few international and national surveys using a system-
atic approach have studied drug use in the workplace: 
the Center for Behavioral Health Statistics and Qual-
ity (CBHSQ) report regarding substance use and sub-
stance use disorder by industry published by the Sub-
stance Abuse and Mental Health Services Administration 
(SAMHSA) reported an annual prevalence of illicit drug 
use of 9.5% among workers in the USA between the years 
2008-2012  [3]. In Europe, there is a lack of up-to-date 
and high quality epidemiological data about prevalence 
of drug use in the workplace. The trucking sector, in par-
ticular, is an important cause for concern: truck-drivers 
are a vulnerable working population due to a wide variety 
of hazards [4-6] including physical and ergonomic ones 
with the risk of developing musculoskeletal disorders [7], 
hypertension [8], obstructive sleep apnea (OSA) and sleep 
deprivation  [9, 10], exposure to diesel exhaust and risk 
of developing lung cancer [11]. Stressful conditions due 
to irregular working schedules, night shifts, being distant 
from families for long periods [12], the need for constant 
mental alertness, and high productivity demands  [13] 
increase risky behaviors such as smoking, drinking, us-
ing psychoactive substances, and having casual sexual 
contacts [14]. In particular, psychoactive drugs affect the 
functioning of the brain by delaying cognitive and execu-
tive functions, which may lead to impaired driving [15]. 
These can have a relevant impact on truck-drivers’ health, 
as well as on work safety, increasing the risk of injuries 
and traffic accidents [16, 17], often fatal: 21% of all lethal 
injuries occurred among “transportation and warehous-
ing” workers in Iowa in 2005-2009 had a positive toxicol-
ogy test for substance use [18]. Indeed, while the effects 
of ethanol on driving have been thoroughly studied by the 
literature, as shown in the previously published article by 
the Authors [19], the impact of other substances on driv-
ing is not as clear. The vast variety of substance classes, 
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each with specific effects on physical and mental health, 
requires a detailed understanding of the interaction and ef-
fect on work specific tasks. Italian law has identified sev-
eral occupational categories as at risk of harm to their and 
others’ health and safety, to which it prohibits drug use, 
even occasional  [20]. Nevertheless, not much is known 
regarding on site health surveillance and drug testing in 
this occupational sector.
A comprehensive analysis of this issue can adequately 
inform policy-makers in order to address legislative 
shortcomings and implement preventive measures in the 
workplace, reducing in turn the contribution of work-re-
lated drug health problems arising from working condi-
tions to the general public.
The aim of the present systematic review and meta-
analysis is to provide Occupational Health Profession-
als  and policy-makers with updated epidemiological 
data regarding drug consumption among truck-drivers, 
in order to reduce the knowledge gap, and in turn to al-
low the implementation of effective countermeasures 
taking place in the workplace. The reduction of drug-
related health problems induced by working condi-
tions will also beneficially contribute to public health. 
This study adds to the findings regarding alcohol con-
sumption in this occupational category, presented in our 
previously published article, and significantly updates 
and expands, through a rigorous quantitative analysis, 
the work performed by Girotto and colleagues [4].
Materials and methods
Systematic review
The current systematic review of the literature with me-
ta-analysis and meta-regressions is reported according to 
the Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) guidelines  [21]. The study 
protocol was registered in the “International database 
of prospectively registered systematic reviews in health 
and social care” (PROSPERO database [22]; registration 
code CRD42016037077) [23]. The results of the study 
are reported in line with the PRISMA guidelines [24].
Briefly, a comprehensive pool of scholarly databases 
(namely, PubMed/MEDLINE (NLM), Scopus, SciVerse 
ScienceDirect, Science Citation Index Expanded (SCIE) 
and Social Sciences Citation Index from ISI/Web of Sci-
ence, ProQuest Research Library, ABI/INFORM, CB-
CA), via the UNO per TUTTI Primo Central (Ex Libris) 
platform) was searched from inception using the follow-
ing string of keywords: (truckers OR truck-drivers OR 
lorry OR commercial vehicles OR large good vehicles 
OR large vehicles OR heavy vehicles OR long vehicles 
OR trucking industry OR haul transport) AND (drugs 
OR psychostimulants OR psychoactive substances OR 
amphetamine OR benzodiazepines OR cocaine OR her-
oin OR opioids OR cannabis OR cannabinoids). Medi-
cal Subject Headings (MeSH) terms and wild-card op-
tion (truncated words) were used when necessary. Last 
search was carried out on 3rd December 2018. No lan-
guage restriction or time filter were applied. Gray litera-
ture was consulted via Google Scholar. Further details of 
the search strategy are reported in Table I. 
Literature search was performed by 2  researchers inde-
pendently (NLB and AR). In case of disagreement, con-
sensus was reached through discussion and consultation. 
Based on the PECO criteria, articles were included if: 
1) focused on truck-drivers (P = truck-drivers); 2) inves-
tigating drug consumption (E = exposure to abuse sub-
stances); 3)  stratifying according to parameters such as 
age, gender, marital status, experience years, mean dis-
tance travelled (per trip), work-load, night-shift or educa-
tional level, in terms of primary schooling level (C = any 
comparison); and 4)  reporting prevalence rate of drug 
consumption (O = drug consumption rate). Concerning 
the study design, articles were selected if devised as prev-
alence studies. Articles were excluded if not meeting with 
the above-stated PECO criteria and if designed as letter 
to editor, editorial, commentary, expert opinion, review 
article (of any type). 
Reviews were, anyways, scanned for reducing the 
chance of missing potentially relevant articles. Relevant 
information was extracted from each included article by 
two researchers independently (NLB and AR). In case 
of disagreement, a third researcher (GD) acted as final 
referee. For data extraction, an ad hoc Excel spreadsheet 
was designed and utilized. Besides tables, relevant infor-
mation was summarized by means of a narrative review. 
Methodological appraisal of studies quality 
Study quality was assessed utilizing the “Joanna Briggs In-
stitute Critical Appraisal tools for use in JBI Systematic Re-
views-Checklist for Prevalence Studies”. This tool explores 
different domains of quality: namely, 1) the appropriateness 
of the sample frame to address the target population; 2) the 
participants sampling technique; 3) the adequateness of the 
sample size; 4) the completeness of the description and de-
tails concerning the study subjects and the setting; 5) the 
coverage of the sample; 6) the validity of the methods; and 
7) their reliability; 8) the appropriateness of the statistical 
analyses; and, finally, 9) the adequateness of the response 
rate. Based on the JBI tool, studies were deemed of high, 
medium and low quality, respectively.
Meta-analysis 
For each outcome (amphetamine, benzodiazepines, canna-
bis, cocaine, heroin, opioid, OTC stimulants, overall drug 
consumption and poliabuse rates), effect size (ES) was 
computed pooling together the various prevalence rates, 
using the logit transformation approach.
Heterogeneity among studies was quantitatively assessed 
computing the I2 statistics. An amount greater than 50% 
was considered statistically significant [25, 26]. Based on 
the amount of heterogeneity, a fixed- or a random-effect 
model was chosen. 
Publication bias was studied both by visually inspecting the 
funnel plot in terms of asymmetry and by computing the 
Egger’s regression test [27] and the Duval and Tweedie’s 
trim-and-fill analysis [28]. Sensitivity analyses and cumu-
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lative meta-analyses were further performed, in order to 
verify the reliability and the consistency of the findings. 
All analyses were carried out with the commercial software 
Comprehensive Meta-Analysis (CMA version 3.0, for Win-
dows). 




The initial search resulted in a pool of 174,712 articles. 
After deleting duplicates, a set of 152,367  unique items 
was obtained. Screening titles and/or abstracts led to the 
exclusion of 153,132 items. A pool of articles was re-
trieved and accessed in full-text. Finally, 51 studies were 
included (Fig. 1). 
Investigations were carried out between 1983 and 2018. 
Sample sizes ranged from 30 to 11,242 subjects, with a 
total of 43,673 participants. 31 studies investigated drug 
consumption among truck-drivers utilizing question-
naires, whilst 14 and 6 studies utilized urine and saliva 
samples, respectively. 35 studies were performed in the 
Americas (1 in Canada, 6 in the USA, and 28 in Brazil), 
5 in Asia (3 in Thailand, 1 in Pakistan, and 1 in Iran), 
5 in Europe (3 in Italy, 1 in France and 1 in Norway), 
4 in Australia and 2 in Africa (1 in Morocco and 1 in 
Nigeria). 




Questionnaire Urine sample Saliva sample
Amphetamine 21.3% [95%CI 15.7-28.1] 3.8% [95%CI 1.7-8.2] 1.3% [95%CI 0.7-2.4]
Benzodiazepines 1.0% [95%CI 0.1-6.1] 0.4% [95%CI 0.2-0.6] NA
Cannabis 5.9% [95%CI 3.5-9.8] 2.1% [95%CI 1.0-4.3] 0.5% [95% 0.3-1.0%]
Cocaine 2.2% [95%CI 1.2-4.1] 1.1% [95%CI 0.7-2.0] 1.1% [95%CI 0.4-3.1]
Opioid 4.3% [95%CI 0.6-26.4] 2.0% [95%CI 0.6-6.6] NA
OTC stimulants 4.1% [95%CI 2.7-6.2] 9.0% [95%CI 4.3-18.0] NA
Overall drug consumption 27.6% [95%CI 17.8-40.1] 6.1% [95%CI 2.9-12.4] 4.1% [95%CI 1.2-13.1]
Poliabuse 2.7% [95%CI 0.2-25.6] 0.6% [95%CI 0.1-4.8] 0.3% [95%CI 0.1-0.7]
NA: not available; OTC: over-the-counter.
Fig. 1. PRISMA 2009, flow diagram. The process of retrieving and selecting articles adopted in the present systematic review and meta-
analysis.
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Age went from 33.5 to 43.85 years, with male percent-
age varying in the range 90.6-100.0%. Concerning the 
marital status, percentage of married subjects ranged 
from 62.0% to 94.9%. Percentage of truck-drivers 
with at least primary education varied between 35.2% 
and 100.0%, with schooling years going from 4.6 to 
8.7  years. Work-load ranged from 7.8 to 14.8 hours, 
with mean distance travelled varying between 270 km 
and 1,159.7 km. Percentage of truck-drivers working for 
companies was highly variable, in the range 0-76%. Ex-
perience years went from 10 to 18.5 hours. Finally, per-
centage of truck-drivers doing night-shifts ranged from 
10.7% to 33.0%. 
Concerning the outcomes, amphetamine consumption 
ranged from 0.0% to 82.5%, whereas cannabis and co-
caine use went from 0.0% to 29.9%, and from 0.1% to 
8.9%, respectively. Heroin consumption varied between 
0.1% and 0.9%. Opioid use ranged from 0.2% to 33.0%, 
while benzodiazepines consumption went from 0.0% to 
2.1%. OTC stimulant use ranged from 4% to 13%, while 
poliabuse prevalence was more variable (0.0-8.9%). Fi-
nally, overall drug use was in the range 1.3-80.4%.
Amphetamine consumption 
Based on questionnaires, the overall amphetamine con-
sumption rate was 21.3% ([95%CI 15.7-28.1], z = – 6.94, 
p < 0.0001, k = 22) (Supplementary Fig. 1A). Due to the 
high statistically significant heterogeneity (I2 = 97.15%), 
a random-effect model was applied (I2 = 64.91%). No 
evidence of publication bias could be found. At the meta-
regression analyses, significant moderators were found 
to be country (Q = 39.20, p < 0.0001, with the highest 
ES in Brazil, and the lowest ES in Nigeria) (Supplemen-
tary Fig. 2), age (coefficient = – 0.24, SE = 0.06 [95%CI 
– 0.36 to – 0.12], z = – 3.82, p = 0.0001) (Supplementary 
Fig. 3), marriage (coefficient = – 0.02, SE = 0.01 [95%CI 
–  0.04 to 0.00], z  =  –  1.99, p  =  0.0470), experience 
years (coefficient = – 0.34, SE = 0.10 [95%CI – 0.54 to 
– 0.14], z = – 3.37, p = 0.0008) (Supplementary Fig. 4), 
working for companies (coefficient = – 0.04, SE = 0.01 
[95%CI – 0.06 to – 0.01], z = – 2.72, p = 0.0065) and 
primary schooling level (coefficient = – 0.02, SE = 0.01 
[95%CI – 0.03 to – 0.01], z = – 2.69, p = 0.0071). Male 
(p = 0.1040), mean distance (p = 0.7928) and work-load 
(p = 0.3804) were not statistically significant. For the 
other moderators, meta-regression analyses could not be 
run due to insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
amphetamine consumption rate was 3.8% ([95%CI 1.7-
8.2], z = – 7.70, p < 0.0001, k = 13) (Supplementary 
Fig. 5A). Due to the high statistically significant hetero-
geneity (I2 = 97.36%), a random-effect model was car-
ried out (I2 = 42.38%). No evidence of publication bias 
could be detected. At the meta-regression analyses, only 
country (Q = 23.64, p < 0.0001, with the highest ES in 
Thailand and the lowest ES in France) resulted a sta-
tistically significant moderator. Age (p = 0.1673), male 
(p = 0.0511) were not statistically significant modera-
tors. For the other moderators, meta-regression analyses 
could not be run due to insufficient number of studies. 
Based on studies utilizing saliva samples, the overall 
amphetamine consumption rate was 1.3% ([95%CI 0.7-
2.4], z = – 13.63, p < 0.0001, k = 5) (Supplementary 
Fig.  6A). Due to the high statistically significant het-
erogeneity (I2  =  83.68%) a random-effect model was 
applied (I2 = 47.67%). No evidence of publication bias 
could be found. For all the moderators, meta-regression 
analyses could not be run due to insufficient number of 
studies. 
Cannabis consumption 
Based on questionnaires, the overall cannabis consumption 
rate was 5.9% ([95%CI 3.5-9.8], z = – 9.88, p < 0.0001, 
k = 10) (Supplementary Fig. 1B). Due to the high statisti-
cally significant heterogeneity, (I2 = 96.81%), a random-
effect model was carried out (I2 = 62.28%). No evidence 
of publication bias could be found. At the meta-regression 
analyses, a significant moderator was found to be only 
country (Q = 15.85, p = 0.0146, with the highest ES in 
Pakistan, and the lowest ES in Iran). Age (p = 0.1044), 
male (p = 0.5799), marriage (p = 0.5939), mean distance 
(p  =  0.4235), experience years (p  =  0.7688), working 
for companies (p = 0.2192), and primary schooling level 
(p = 0.3200) were not statistically significant. For the other 
moderators, meta-regression analyses could not be run due 
to insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
cannabis consumption rate was 2.1% ([95%CI 1.0-
4.3], z  =  –  9.97, p  <  0.0001, k  =  11) (Supplementary 
Fig. 5B). Due to the high statistically significant hetero-
geneity (I2 = 97.62%), a random-effect model was cho-
sen (I2  =  4.52). At the meta-regression analyses, only 
age (coefficient = – 0.50, SE = 0.09 [95%CI – 0.68 to 
– 0.33], z = – 5.56, p < 0.0001) resulted a statistically sig-
nificant moderator. Country (Q = 3.97, p = 0.5537), male 
(p = 0.2427) were not statistically significant moderators. 
For the other moderators, meta-regression analyses could 
not be run due to insufficient number of studies. 
Based on studies utilizing saliva samples, the overall 
cannabis consumption rate resulted 0.5% ([95% 0.3-
1.0%], z = – 15.69, p < 0.0001, k = 4) (Supplementary 
Fig. 6B). Due to the high statistically significant hetero-
geneity (I2 = 68.12%), a random-effect model was ap-
plied (I2 = 0.00%). The visual inspection of the funnel 
plot showed evidence of publication bias. At the Duval 
and Tweedie’s trim-and-fill analysis, 2 studies were cen-
sored, resulting in a “real” ES of 0.3% ([95%CI 0.1-0.7], 
Q = 33.21) (Supplementary Fig. 7). For all the modera-
tors, meta-regression analyses could not be run due to 
insufficient number of studies. 
Cocaine consumption 
Based on questionnaires, the overall cocaine consump-
tion rate was 2.2% ([95%CI 1.2-4.1], z  =  –  11.75, 
p < 0.0001, k = 9) (Supplementary Fig. 1C). Due to the 
high statistically significant heterogeneity (I2 = 91.66%), 
a random-effect model was applied (I2 = 50.78%). No 
evidence of publication bias could be found. Coun-
try (Q  =  6.06, p  =  0.1951), age (p  =  0.2460), male 
(p  =  0.2433), marriage (p  =  0.0541), mean distance 
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(p = 0.8952), experience years (p = 0.2604), working 
for companies (p  =  0.3851), primary schooling level 
(p = 0.5713) were not statistically significant modera-
tors. For the other moderators, meta-regression analyses 
could not be run due to insufficient number of studies. 
Based on studies utilizing urine samples, the over-
all cocaine consumption rate was 1.1% ([95%CI 0.7-
2.0], z = – 15.59, p < 0.0001, k = 10) (Supplementary 
Fig. 5C). Due to the high statistically significant hetero-
geneity (I2 = 88.74%), a random-effect model was car-
ried out (I2 = 19.33%). No evidence of bias was found. 
At the meta-regression analyses, no statistically sig-
nificant moderators could be found. Country (Q = 6.47, 
p = 0.1668), age (p = 0.5273), male (p = 0.3568) were 
not statistically significant moderators. For the other 
moderators, meta-regression analyses could not be run 
due to insufficient number of studies. 
Based on studies utilizing saliva samples, the overall co-
caine consumption rate resulted 1.1% ([95%CI 0.4-3.1], 
z = – 8.29, p < 0.0001, k = 3) (Supplementary Fig. 6C). 
Due to the high statistically significant heterogene-
ity (I2 =  88.18%), a random-effect model was chosen 
(I2 = 0.00%). No evidence of bias publication could be 
found. 
Opioid consumption 
Based on questionnaires, the overall opioid consumption 
rate was 4.3% ([95%CI 0.6-26.4], z = – 2.92, p = 0.003, 
k = 4) (Supplementary Fig. 1D). Due to the high statisti-
cally significant heterogeneity (I2 = 98.12%), a random-
effect model was performed (I2 = 0.00%). No evidence 
of publication bias could be found. At the meta-regres-
sion analyses, only age (coefficient = – 0.49, SE = 0.13 
[95%CI – 0.75 to – 0.23], z = – 3.70, p = 0.0002) re-
sulted a statistically significant moderator. For the other 
moderators, meta-regression analyses could not be run 
due to insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
opioid consumption rate was 2.0% ([95%CI 0.6-6.6], 
z = – 6.13, p < 0.0001, k = 4) (Supplementary Fig. 5D). 
Due to the high statistically significant heterogene-
ity (I2 =  95.97%), a random-effect model was chosen 
(I2 = 0.00%). No evidence of publication bias was found. 
It was not possible to compute meta-regressions due to 
insufficient number of studies/missing information. 
Benzodiazepines consumption 
Based on questionnaires, the overall benzodiazepines 
consumption rate was 1.0% ([95%CI 0.1-6.1], z = – 4.81, 
p < 0.0001, k = 2). Due to the high statistically signifi-
cant heterogeneity (I2 = 70.57%), a random-effect mod-
el was carried out (I2 = 0.00%). Since there were only 
2  studies, it was not possible to conduct a publication 
bias analysis and meta-regressions.
Based on studies utilizing urine samples, the overall 
benzodiazepines consumption rate was 0.4% [95%CI 
0.2-0.6], z = – 21.71, p < 0.0001, k = 4). Due to the ab-
sence of heterogeneity (I2 = 0.00%), a fixed-effect model 
was applied. There was no evidence of publication bias. 
For all the moderators, meta-regression analyses could 
not be run due to insufficient number of studies. 
Over-the-counter stimulant consumption 
Based on questionnaires, the overall OTC stimulant con-
sumption rate was 4.1% ([95%CI 2.7-6.2], z = – 14.09, 
p < 0.0001, k = 3). Due to the high statistically signifi-
cant heterogeneity (I2 = 76.18%), a random-effect model 
was conducted (I2 = 28.35%). The visual inspection of 
the funnel plot gave evidence of publication bias. At the 
Duval and Tweedie’s trim-and-fill analysis, one study 
was censored, with a “real” ES of 3.5% ([95%CI 2.3-
5.3], Q = 15.46) (Supplementary Fig. 8). For all modera-
tors, meta-regression analyses could not be run due to 
insufficient number of studies. 
Based on studies utilizing urine samples, the overall 
OTC stimulant consumption rate was 9.0% ([95%CI 
4.3-18.0], k = 2). Due to the high statistically significant 
heterogeneity (I2 = 92.41%), a random-effect model was 
chosen (I2 = 0.00%). Since there were only 2 studies, it 
was not possible to conduct a publication bias analysis 
and meta-regressions. 
Poliabuse rate 
Based on questionnaires, the overall poliabuse rate was 
2.7% ([95%CI 0.2-25.6], z = – 2.80, p = 0.005, k = 2). 
Due to the high statistically significant heterogene-
ity (I2 = 96.14%), a random-effect model was applied 
(I2 = 0.00%). Since there were only 2 studies, it was not 
possible to conduct a publication bias analysis and meta-
regressions. 
Based on studies utilizing urine samples, the overall 
poliabuse rate was 0.6% ([95%CI 0.1-4.8], z = – 4.77, 
k = 5). Due to the high statistically significant heteroge-
neity (I2 = 90.76%), a random-effect model was carried 
out (I2 = 0.00%). No evidence of publication bias could 
be found. At the meta-regression analyses, only coun-
try (Q = 17.45, p = 0.0002, with the highest ES in the 
USA and the lowest ES in Italy) resulted a statistically 
significant moderator. For the other moderators, meta-
regression analyses could not be run due to insufficient 
number of studies.
Based on studies utilizing saliva samples, the overall 
poliabuse rate was 0.3% ([95%CI 0.1-0.7], z = – 12.98, 
p < 0.0001, k = 3). Due to the statistically significant 
heterogeneity (I2 = 61.68%), a random-effect model was 
performed (I2 = 0.00%). No evidence of publication bi-
as could be found. For all moderators, meta-regression 
analyses could not be conducted due to insufficient num-
ber of studies. 
Overall drug consumption
Based on questionnaires, the pooled overall drug con-
sumption rate was 27.6% ([95%CI 17.8-40.1], z = – 3.36, 
p = 0.001, k = 14) (Supplementary Fig. 1E). Due to the 
high statistically significant heterogeneity (I2 = 99.04%), 
a random-effect model was applied (I2 = 21.28%). There 
was no evidence of publication bias. At the meta-regres-
sion analyses, only age (coefficient = – 0.22, SE = 0.07 
[95%CI – 0.36 to – 0.08], z = – 3.13, p = 0.0018) result-
ed a statistically significant moderator. On the contrary, 
country (Q = 1.47, p = 0.8326), male (p = 0.9460), mar-
riage (p = 0.3583), mean distance (p = 0.9759), experi-
ence years (p = 0.1128), work-load (p = 0.9902), working 
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for companies (p = 0.8486), and primary schooling level 
(p = 0.3112) were not statistically significant modera-
tors. For the other moderators, meta-regression analyses 
could not be run due to insufficient number of studies. 
Based on studies utilizing urine samples, the pooled 
overall drug consumption rate was 6.1% ([95%CI 2.9-
12.4], p  <  0.0001, k  =  8) (Supplementary Fig.  5E). 
Due to the high statistically significant heterogeneity 
(I2 = 98.44%), a random-effect model was conducted 
(I2 = 0.00%). The visual inspection of the funnel plot 
showed evidence of publication bias. At the Duval 
and Tweedie’s trim-and-fill analysis, 1 study was cen-
sored, resulting in a “real” ES of 5.1% ([95% 2.4-10.1], 
Q = 543.42) (Supplementary Fig. 9). At the meta-regres-
sion analyses, only age (coefficient = – 0.36, SE = 0.09 
[95%CI – 0.53 to – 0.19], z = – 4.13, p < 0.0001) re-
sulted a statistically significant moderator. Country 
(Q = 1.65, p = 8003), and male (p = 0.8430) were not 
statistically significant moderators. For the other mod-
erators, meta-regression analyses could not be run due 
to insufficient number of studies. 
Based on studies utilizing saliva samples, the pooled 
overall drug consumption rate was 4.1% ([95%CI 1.2-
13.1], z = – 4.90, p < 0.0001, k = 5) (Supplementary 
Fig.  6D). Due to the high statistically significant het-
erogeneity (I2 =  98.89%), a random-effect model was 
conducted (I2 = 0.00%). For all the moderators, meta-
regression analyses could not be run due to insufficient 
number of studies.
Pooled drug consumption rates stratified according to 
the type of study are summarized in Table I.
Study quality
Findings of the critical appraisal of included studies are 
shown in Table II.
Discussion
To the best of our knowledge, this is the first systematic 
review with meta-analysis and meta-regressions on drug 
consumption rate among truck-drivers. Considering the 
meta-analysis performed on data extracted from ques-
tionnaires, the findings show an increased prevalence of 
drug use among truck-drivers, especially central nervous 
system (CNS) stimulants, compared to the general popu-
lation. In particular, the overall annual prevalence of am-
phetamine use among truck-drivers of 21.3%, compared 
to the estimated global prevalence of consumption in the 
general population of 0.7% [1], shows an almost 30-fold 
higher rate. 
Similarly, but to a lesser degree, the results regarding 
cocaine use showed a higher prevalence (2.2%) com-
pared to the general population (0.37%) [1]. In previous 
studies, stimulant consumption among truck-drivers has 
been associated with night shifts, length of travel and 
younger age [17, 75, 76]. Other authors have suggested 
that also external factors play a role, such as productiv-
ity-based payments [73]. In the present analysis, being 
younger and having less professional experience showed 
the most significant correlations with stimulant use. 
Drivers often take stimulants as a form of Performance En-
hancing Drugs (PEDs), in order to sustain ever increasing 
work-loads and busy work schedules. Several studies per-
formed in controlled clinical settings have suggested that 
low dose amphetamines could improve psychomotor skills, 
such as driving ability, even in fatigued subjects [77]. How-
ever, chronic and high dose users, taken in real life settings, 
showed poorer compliance with traf"c rules and working 
hours regulations [78], with an increased risk of traffic acci-
dents [79], mainly as a consequence of after effects such as 
hypersomnolence and fatigue [80, 81]. Some authors have 
suggested that blood concentration above 0.27-0.53 mg/l 
is associated with psychomotor impairment  [79]. Similar 
considerations have been made regarding cocaine use and 
its effects on psychomotor skills  [82-85]. Amphetamine 
use has been estimated to increase the risk of fatal accidents 
by 5-times, causing in 2013 around half of all road traffic 
deaths caused by illicit drug consumption worldwide, re-
sulting in around 20 thousand deaths [15]. 
The European Agency for Safety and Health at Work (EU-
OSHA) has acknowledged the spread and normalization 
Tab. II. Critical appraisal of studies included in the present systematic review and meta-analysis.
Study Domain I Domain II Domain III Domain IV Domain V Domain VI Domain VII Domain VIII Domain IX
Bombana et al. 
2017 [29] Yes No Yes Yes Yes Yes Yes Yes Yes
Cerqueira et al. 
2011 [30] Yes No No Yes Yes Yes Yes Yes Yes
Couper et al. 
2002 [31] No Yes Yes Yes Yes Yes Yes Yes Yes
De Oliveira et al. 
2015 [32] Yes No Yes Yes Yes Yes Yes Yes Yes
De Oliveira et al. 
2016 [33] Yes No Yes Yes Yes Yes Yes Yes Yes
Drummer et al. 
2007 [34] No Yes Yes Yes Yes Yes Yes Yes Yes
Girotto et al.
2015 [17] Yes No Yes Yes Yes Yes Yes Yes Yes
Gjerde et al.
2012 [35] No Yes Yes Yes Yes Yes Yes Yes Yes
Gjerde et al.
2014 [36] No Yes Yes Yes Yes Yes Yes Yes Yes
continues
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Tab. II. follows.
Study Domain I Domain II Domain III Domain IV Domain V Domain VI Domain VII Domain VIII Domain IX
Guinn et al.
1983 [37] No No No No Yes No No Yes Yes
Ingsathit et al. 
2009 [38] No Yes Yes Yes Yes Yes Yes Yes Yes
Knauth et al. 
2011 [39] Yes No Yes No Yes No No Yes Yes
Korelitz et al. 
1993 [16] Yes No Yes No Yes Yes Yes Yes Yes
Labat et al.
2008 [40] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Laraqui et al.
2011 [41] Yes No Yes Yes Yes No No Yes Yes
Lemire et al.
2002 [42] No Yes Yes No Yes Yes Yes Yes Yes
Leopoldo et al. 
2015 [43] Yes No Yes Yes Yes Yes Yes Yes Yes
Leyton et al. 
2012 [44] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Lund et al.
1988 [45] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Maarefvand et al.
2016 [46] Yes No Yes Yes Yes Yes Yes Yes Yes
Mabbott and 
Hartley 1999 [47] Yes No Yes Yes Yes Yes Yes Yes No
Mansur Ade et al. 
2015 [48] No Yes Yes No Yes Yes Yes Yes Yes
Masson, Monteiro 
2010 [49] Yes
No No Yes Yes No No Yes Yes
Mieczkowski
2010 [50] No Yes Yes Yes No Yes Yes Yes Yes
Mir et al.
2012 [51] Yes Yes Yes No Yes No No Yes Yes
Mongkolsirichaikul 
et al. 1988 [52] Yes Yes No Yes Yes Yes Yes Yes Yes
Moreira, Gadani 
2009 [53] No No No No Yes No No Yes Yes
Nascimento et al. 
2007 [54] Yes No No No Yes No No Yes Yes
Okpataku
2016 [55] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Peixe et al.
2014 [56] Yes No No Yes Yes Yes Yes Yes No
Penteado et al. 
2008 [57] Yes No Yes Yes Yes No No Yes Yes
Pereira et al.
2014 [58] Yes No No Yes Yes No No Yes Yes
Pidetcha et al. 
1995 [59] No No No No Yes Yes Yes Yes Yes
Pinheiro et al. 
2015 [60] Yes No No Yes Yes No No Yes Yes
Pinho 
2005 [61] Yes No Yes Yes Yes Yes Yes Yes Yes
Remor et al. 
2015 [62] Yes No Yes Yes Yes No No Yes Yes
Riva et al. 
2010 [63] Yes No Yes Yes Yes No No Yes Yes
Riva et al. 
2018 [64] Yes No Yes Yes Yes No No Yes Yes
Sangaleti et al. 
2014 [65] Yes No Yes Yes Yes No No Yes Yes
Silva et al. 
2003 [66] No Yes Yes No Yes Yes Yes Yes Yes
continues
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of stimulant use among certain groups of workers, par-
ticularly transportation workers, shift workers, and work-
ers in high pressure, competitive or bullying work cul-
tures [86]. It highlighted the need to evaluate the potential 
effect of non-medical drug used as cognitive enhancers in 
the workplace, and to consider the work environment and 
the interaction between workers and their working condi-
tions as important factors in the use of PEDs. 
Opiates, opioids, and CNS depressants, such as can-
nabinoids and benzodiazepines, showed a lower preva-
lence in the study population, and a smaller difference 
compared to the prevalence in the general population. 
In particular regarding cannabinoid use, the relatively 
high prevalence shown (5.9%), with the highest rates ex-
tracted from North American and European studies, fol-
lows the overall increasing rate of recreational and medi-
cal use of this type of drug in the general population: 
while an estimated 3.9% of the global population has 
used cannabinoids in the previous year, in North Amer-
ica the prevalence was higher at 13% [1], reaching over 
14% in the European Union with an increasing trend of 
high-risk use, meaning consuming cannabinoids 20 or 
more days in the past month [2]. Many CNS depressant 
have been found to reduce lane control by increasing the 
standard deviation of lateral position (SDLP)  [87-93]. 
Cannabis has been shown to impair cognitive, particu-
larly affecting working memory and divided attention, 
and psychomotor performances, increasing the chance 
of road accidents  [94]: according to systematic review 
and meta-analysis performed by Asbridge and collabo-
rators, acute cannabis consumption among drivers dou-
bles the risk of crashes compared to non-user [95]. 
Authors have suggested that tetrahydrocannabinol (THC) 
impairs mainly lateral control of the vehicle, while not af-
fecting longitudinal control [96, 97]. Moreover, interaction 
between cannabis and alcohol has been shown to have an 
additive effect on driving performance [91, 94, 98, 99] caus-
ing an increased risk of road accidents [100]. Indeed, can-
nabinoids are estimated to cause one fifth of all road traffic 
deaths caused by illicit drug consumption [15]. The impor-
tance of cannabis use in the workplace may grow further 
as countries reform medicinal and recreational cannabinoid 
laws enabling an increase in the rate of consumption [101]. 
Concerning the results of opiate/opioid use among truck-
drivers, the present analysis shows a prevalence of 4.3%, 
significantly higher compared to the rate of persons who 
use opiates and persons who use prescription opioids for 
non-medical purposes among the general population equal 
to 0.7% worldwide [1], and 0.4% in Europe [2]. 
However, similarly to cannabis, data show that there is a 
growing trend in the use of prescription drugs such as opi-
oids and sedatives, for medical and non-medical reasons, 
reaching epidemic proportions in some Western countries. 
In particular, past-year users of opioids in North America 
have reached a prevalence of 4.2% [1], similar to the re-
sults found in the present study. Moreover, opioids cause 
most of the negative health impact of drug use, account-
ing for three quarters of deaths from drug use disorders in 
2015 [1]. Although the role of opiates and opioid use in 
impairing driving ability is still unclear [102-106], there 
is suggestive evidence that opioids can cause an increased 
risk of vehicle collisions [1, 107]. 
Although the consumption of benzodiazepine was not 
found to be as common among truck-drivers, it must not 
be underestimated, as there is ample evidence of their 
impairing effect on driving skills, particularly regarding 
long-term benzodiazepines  [108-110]. Moreover, non-
medical use of benzodiazepines is the most common 
type of misuse of prescription drugs in the world [1].
Concerning drug testing for recent use, the results obtained 
through saliva sampling showed generally lower rates than 
those found on urine. This might be explained by the fact 
that urine drug testing can detect consumption occurred 
days or weeks before the sampling, resulting in low speci-
ficity for recent substance use. Research has suggested 
that saliva sampling has a stronger correlation with blood 
concentrations compared to urine, being also easier and 
faster to analyze and less intrusive to drivers  [111-113]. 
However, there is a lack of conclusive evidence, with other 
authors considering urine testing as a more accurate meth-
od for identification of substance use and disorders in the 
workplace [114]. Based on the prevalence of overall drug 
use obtained through biological sampling, around 1 every 
20 workers was driving under the influence of drugs. It is 
Tab. II. follows.
Study Domain I Domain II Domain III Domain IV Domain V Domain VI Domain VII Domain VIII Domain IX
Sinagawa et al. 
2014 [67] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Souza et al.
2005 [68] Yes No Yes Yes Yes No No Yes Yes
Starmer et al. 
1997 [69] No No Yes No Yes Yes Yes Yes Yes
Takitane et al. 
2012 [70] Yes Yes Yes Yes Yes Yes Yes Yes Yes
Teles et al.
2008 [71] Yes No Yes Yes Yes Yes Yes Yes Yes
Valway et al.
2009 [72] Yes No Yes Yes Yes Yes Yes Yes Yes
Williamson
2007 [73] Yes No Yes Yes Yes No No Yes Yes
Yonamine et al. 
2012 [74] Yes Yes Yes Yes Yes Yes Yes Yes Yes
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worth noting that the country of origin of the driver was an 
often found association with drug use. Indeed, considering 
the data obtained from the included studies, there appears 
to be a pattern of consumption of specific substances in 
different areas, such as prevalent stimulant use in South 
America, cannabis use in North America and Europe, and 
opioid use in parts of Asia, likely because of availability, as 
well as historic and cultural reasons. 
Overall, the findings of the present study, adding to the re-
sults of the previously published systematic review and me-
ta-analysis concerning at-risk drinking, show that substance 
use is widespread among truck-drivers globally, putting 
workers and the general public at an increased risk of harm. 
The EU Action Plan on Drugs 2017-2020 states that, in or-
der to reduce and prevent drug use, effective evidence-based 
prevention measures must take into consideration situational 
factors, including workplace conditions [115]. There is in-
deed an urgent necessity for updated epidemiological data 
and research studying effective Occupational Health Promo-
tion programs, particularly in Europe, required in order to 
make and enforce effective policies, putting in place coun-
termeasures such as regular worksite drug testing, which has 
been shown to deter drug use among workers [116], as well 
as assessing working conditions that facilitate drug consump-
tion, such as excessive workloads demanded by companies.
Strengths and limitations
The strengths of our study consist in its methodologi-
cal rigor, reproducibility and transparency. We depos-
ited a priori study protocol, which further corroborates 
our meta-analysis. However, despite its novelty and its 
methodological robustness, our study is not without lim-
itations, which should be properly acknowledged. 
The high statistically significant heterogeneity may affect 
the generalization of the findings and calls up for caution in 
their interpretation. For some outcomes, few studies were 
available. In some cases, such paucity limited the possibil-
ity of conducting a full extensive e series of analyses, in-
cluding publication bias analysis and meta-regressions.
Conclusions
The present systematic review of the literature with 
meta-analysis and meta-regressions showed a relevant 
drug consumption rate among truck-drivers. As such, 
this study has practical implications for Occupational 
Physicians dealing with the health and wellbeing of 
truck-drivers. In particular, it appears that truck-drivers 
choose mainly stimulant substances as a form of perfor-
mance enhancing drug, in order to increase productivity. 
However, chronic and high dose consumption has been 
shown to decrease driving skills, placing these profes-
sional drivers, as well as the general public, at risk. 
Current literature is lacking in updated and reliable epi-
demiological data, especially in Europe. Therefore, fur-
ther research in the field is urgently needed in order to 
provide Occupational Health Professionals with up-to-
date data, necessary for the implementation of preven-
tive programs and effective workplace measures. More-
over, this can be useful for decision and policy-makers in 
order to fill the gaps and shortcomings in the regulations. 
Acknowledgements 
Funding sources: this research did not receive any spe-
cific grant from funding agencies in the public, commer-
cial, or not-for-profit sectors.
Conflict of interest statement
None declared.
Authors’ contributions 
GD, NLB and PD conceived the study, AM and AR per-
formed a search of the literature, extracted and collected 
data, AM and AR critically appraised the literature, GD 
and NLB analyzed data, GD, NLB, AM, AR and PD 
drafted and revised the manuscript. All authors have read 
and approved the latest version of the manuscript. 
References
[1] The United Nations Office on Drugs and Crime (UNODC). World 
Drug Report 2018. Available online: www.unodc.org/wdr2018/
prelaunch/WDR18_Booklet_2_GLOBAL.pdf.
[2] European Monitoring Centre for Drugs and Drug Addiction (EM-
CDDA). European Drug Report 2018: trends and developments. 
Available online: www.emcdda.europa.eu/system/files/publica-
tions/8585/20181816_TDAT18001ENN_PDF.pdf.
[3] Substance Abuse and Mental Health Services Administration 
(SAMHSA); Center for Behavioral Health Statistics and Quality 
(CBHSQ). The CBHSQ report: substance use and substance use 
disorder, by industry. Available online: www.samhsa.gov/data/
sites/default/files/report_1959/ShortReport-1959.pdf.
[4] Girotto E, Mesas AE, de Andrade SM, Birolim MM. Psychoactive 
substance use by truck drivers: a systematic review. Occup Environ 
Med 2014;71:71-6. doi: 10.1136/oemed-2013-101452.
[5] Criezzle AM, Bigelow P, Adams D, Gooderham S, Myers AM, 
Thiffault P. Health and wellness of long-haul truck drivers and bus 
drivers: a systematic review and directions for future researches. J 
Transp Health 2017;7:90-109. doi: 10.1016/j.jth.2017.05.359. 
[6] Apostolopoulos Y, Sönmez S, Shattell MM, Belzer M. Work-
site-induced morbidities among truck drivers in the United 
States. AAOHN J 2010;58(7):285-96. doi: 10.3928/08910162-
20100625-01.
[7] van der Beek AJ. World at work: truck drivers. Occup Environ Med 
2012;69:291-5. doi: 10.1136/oemed-2011-100342.
[8] Sieber WK, Robinson CF, Birdsey J, Chen GX, Hitchcock EM, 
Lincoln JE, Nakata A, Sweeney MH. Obesity and other risk fac-
tors: the national survey of U.S. long-haul truck driver health and 
injury. Am J Ind Med 2014;57:615-26. doi: 10.1002/ajim.22293. 
[9] Guglielmi O, Magnavita N, Garbarino S. Sleep quality, obstructive 
sleep apnea, and psychological distress in truck drivers: a cross-sec-
tional study. Soc Psychiatry Psychiatr Epidemiol 2018;53(5):531-
6. doi: 10.1007/s00127-017-1474-x.
[10] Burns N. An integrative review of screening for obstructive sleep 
apnea in commercial vehicle drivers. Workplace Health Saf 
2014;62:114-20. doi: 10.3928/21650799-20140219-05.
[11] Gamble JF, Nicolich MJ, Boffetta P. Lung cancer and diesel ex-
PSYCHOACTIVE DRUG CONSUMPTION AMONG TRUCK-DRIVERS:  
A SYSTEMATIC REVIEW OF THE LITERATURE WITH META-ANALYSIS AND META-REGRESSION
E133
haust: an updated critical review of the occupational epidemiology 
literature. Crit Rev Toxicol 2012;42(7):549-98. doi: 10.3109/1040
8444.2012.690725.
[12] Gay Anderson D, Riley P. Determining standards of care for sub-
stance abuse and alcohol use in long-haul truck drivers. Nurs Clin 
North Am 2008;43:357-65. doi: 10.1016/j.cnur.2008.04.003.
[13] Wagstaff AS, Sigstad Lie JA. Shift and night work and long work-
ing hours - a systematic review of safety implications. Scand J 
Work Environ Health 2011;37:173-85. doi: 10.5271/sjweh.3146.
[14] Zhang X, Chow EP, Wilson DP, Sun X, Zhao R, Zhang J, Jing 
J, Zhang L. Prevalence of HIV and syphilis infections among 
long-distance truck drivers in China: a data synthesis and 
meta-analysis. Int J Infect Dis 2013,17:e2-e7. doi: 10.1016/j.
ijid.2012.07.018.
[15] World Health Organization (WHO). Drug use and road safety: a 
policy brief. 2016. Available online: www.who.int/violence_in-
jury_prevention/publications/road_traffic/Drug_use_and_road_
safety.pdf.
[16] Korelitz JJ, Fernandez AA, Uyeda VJ, Spivey GH, Browdy BL, 
Schmidt RT. Health habits and risk factors among truck drivers 
visiting a health booth during a trucker trade show. Am J Health 
Promot 1993;8:117-23. doi: 10.4278/0890-1171-8.2.117.
[17] Girotto E, de Andrade SM, Mesas AE, González AD, Guidoni CM. 
Working conditions and illicit psychoactive substance use among 
truck drivers in Brazil. Occup Environ Med 2015;72:764-9. doi: 
10.1136/oemed-2015-102868.
[18] Ramirez M, Bedford R, Sullivan R, Anthony TR, Kraemer J, Faine 
B, Peek-Asa C. Toxicology testing in fatally injured workers: a re-
view of five years of Iowa FACE cases. Int J Environ Res Public 
Health 2013;10:6154-68. doi: 10.3390/ijerph10116154.
[19] Bragazzi NL, Dini G, Toletone A, Rahmani A, Montecucco A, 
Massa E, Manca A, Guglielmi O, Garbarino S, Debarbieri N, Du-
rando P. Patterns of harmful alcohol consumption among truck 
drivers: implications for occupational health and work safety from 
a systematic review and meta-analysis. Int J Environ Res Public 
Health 2018;15:1121. doi: 10.3390/ijerph15061121.
[20] Conferenza Unificata. Provvedimento 30 ottobre 2007, Intesa, ai 
sensi dell’articolo 8, comma 6, della legge 5 giugno 2003, n. 131, in 
materia di accertamento di assenza di tossicodipendenza. Available 
online: www.gazzettaufficiale.it/eli/id/2007/11/15/07A09622/sg.
[21] Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew 
M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting 
items for systematic review and meta-analysis protocols (PRIS-
MA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647. 
doi: 10.1136/bmj.g7647. 
[22] Chien PF, Khan KS, Siassakos D. Registration of systematic re-
views: PROSPERO. BJOG 2012;119:903-5. doi: 10.1111/j.1471-
0528.2011.03242.x.
[23] Bragazzi NL, Dini G, Toletone A, Durando P. An Updated 
systematic review with meta-analysis examining prevalence 
of drugs and alcohol use among truck-drivers. PROSPERO 
2016:CRD42016037077. Available online: www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42016037077. 
[24] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 
Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. 
doi: 10.1371/journal.pmed.1000097. 
[25] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-
analysis. Stat Med 2002;21:1539-58. doi: 10.1002/sim.1186.
[26] Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Bo-
tella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 
index? Psychol Methods 2006;11:193-206. doi: 10.1037/1082-
989X.11.2.193.
[27] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-anal-
ysis detected by a simple, graphical test. BMJ 1997;315(7109):629-
34. doi: https://doi.org/10.1136/bmj.315.7109.629.
[28] Duval S, Tweedie R. Trim and "ll: a simple funnel-plot-based 
method of testing and adjusting for publication bias in meta-
analysis. Biometrics 2000;56:455-63. doi: 10.1111/j.0006-
341X.2000.00455.x.
[29] Bombana HS, Gjerde H, Dos Santos MF, Jamt REG, Yonamine 
M, Rohlfs WJC, Muñoz DR, Leyton V. Prevalence of drugs in oral 
fluid from truck drivers in Brazilian highways. Forensic Sci Int 
2017;273:140-3. doi: 10.1016/j.forsciint.2017.02.023.
[30] Cerqueira GS, Siqueira RMP, Freitas APF, Leiros WSB, Freitas 
RM, Silva RC, Fragoso LM. Uso de anfetaminas entre caminho-
neiros - um estudo transversal. Rev Inter 2011;4:76-86.
[31] Couper FJ, Pemberton M, Jarvis A, Hughes M, Logan BK. Preva-
lence of drug use in commercial tractor-trailer drivers. J Forensic 
Sci 2002;47:562-7.
[32] De Oliveira LG, de Souza LM, Barroso LP, Gouvêa MJ, de Almei-
da CV, Muñoz DR, Leyton V. Occupational conditions and the risk 
of the use of amphetamines by truck drivers. Rev Saude Publica 
2015;49:61. doi: 10.1590/S0034-8910.2015049005944.
[33] De Oliveira LG, Leopoldo K, Gouvea MJ, Barroso LP, Gouveia 
PA, Muñoz DR, Leyton V. Prevalence of at-risk drinking among 
Brazilian truck drivers and its interference on the performance of 
executive cognitive tasks. Drug Alcohol Depend 2016;166:218-25. 
doi: 10.1016/j.drugalcdep.2016.07.019.
[34] Drummer OH, Gerostamoulos D, Chu M, Swann P, Boorman M, 
Cairns I. Drugs in oral fluid in randomly selected drivers. Forensic 
Sci Int 2007;170:105-10. doi: 10.1016/j.forsciint.2007.03.028.
[35] Gjerde H, Christophersen AS, Normann PT, Pettersen BS, Sab-
aredzovic A, Samuelsen SO, Mørland J. Analysis of alcohol and 
drugs in oral #uid from truck drivers in Norway. Traffic Inj Prev 
2012;13:43-8. doi:10.1080/15389588.2011.627957.
[36] Gjerde H, Sousa TR, De Boni R, Christophersen AS, Limberger 
RP, Zancanaro I, Oiestad EL, Normann PT, Mørland J, Pechansky 
F. A comparison of alcohol and drug use by random motor vehicle 
drivers in Brazil and Norway. Int J Drug Policy 2014;25:393-400. 
doi: 10.1016/j.drugpo.2014.01.019.
[37] Guinn, B. Job satisfaction, counterproductive behavior and cir-
cumstantial drug use among long-distance truckers. J Psychoactive 
Drugs 1983;15:185-8. doi: 10.1080/02791072.1983.10471947.
[38] Ingsathit A, Woratanarat P, Anukarahanonta T, Rattanasiri S, 
Chatchaipun P, Wattayakorn K, Lim S, Suriyawongpaisal P. 
Prevalence of psychoactive drug use among drivers in Thailand: 
a roadside survey. Accid Anal Prev 2009;41:474-8. doi: 10.1016/j.
aap.2009.01.010.
[39] Knauth DR, Pilecco FB, Leal AF, Seffner F, Teixeira AM. Staying 
awake: truck drivers’ vulnerability in Rio Grande do Sul, Southern 
Brazil. Rev Saude Publica 2012;46:886-93. doi:  0.1590/S0034-
89102012000500016.
[40] Labat L, Fontaine B, Delzenne C, Doublet A, Marek MC, Tellier 
D, Tonneau M, Lhermitte M, Frimat P. Prevalence of psychoac-
tive substances in truck drivers in the Nord-Pas-de-Calais region 
(France). Forensic Sci Int 2008;174:90-4. doi:  10.1016/j.forsci-
int.2007.03.004.
[41] Laraqui S, Laraqui O, Tripodi D, Manar N, Aoudi YE, Caubet A, 
Verger C, Ghailan T, Laraqui CH. Prevalence and risk factors of 
alertness disorders of professional drivers in Morocco. Sante Pub-
lique 2011;23:89-100. doi: 10.3917/spub.112.0089.
[42] Lemire AM, Montégiani M, Dussault C. Alcohol and drug con-
sumption by Québec truck drivers. In: Proceedings of the 16th In-
ternational Conference on Alcohol, Drugs and Traf"c Safety. Mon-
treal, QC, Canada: 4-9 August 2002.
[43] Leopoldo K, Leyton V, Oliveira LG. Alcohol use alone and in 
combination with other drugs among truck drivers on highways in 
São Paulo State, Brazil: a cross-sectional study. Cad Saude Publica 
2015;31:1916-28. doi: 10.1590/0102-311X00047214.
[44] Leyton V, Sinagawa DM, Oliveira KC, Schmitz W, Andreuccetti 
G, De Martinis BS, Yonamine M, Munoz DR. Amphetamine, co-
caine and cannabinoids use among truck drivers on the roads in 
the State of Sao Paulo, Brazil. Forensic Sci Int 2012;215:25-7. 
doi: 10.1016/j.forsciint.2011.03.032.
[45] Lund AK, Preusser DF, Blomberg RD, Williams AF. Drug use 
G. DINI ET AL.
E134
by tractor-trailer drivers. J Forensic Sci 1988;33(3):648-61.
doi: 10.1520/JFS12474J.
[46] Maarefvand M, Kassaie B, Ghiasvand H, Abolfathi Gharibdoosti 
R, Khubchandani J. Sexual and drug use risk behaviors of in-
ternal long distance truck drivers in Iran. Iran J Public Health 
2016;45:606-13.
[47] Mabbott NA, Hartley LR. Patterns of stimulant drug use on 
Western Australian heavy transport routes. Transport Res Part F2 
1999;115-30. doi: 10.1016/S1369-8478(99)00012-1.
[48] Mansur Ade P, Rocha MA, Leyton V, Takada JY, Avakian SD, 
Santos AJ, Novo GC, Nascimento AL, Muñoz DR, Rohlfs WJ. 
Risk factors for cardiovascular disease, metabolic syndrome and 
sleepiness in truck drivers. Arq Bras Cardiol 2015;105:560-5. 
doi: 10.5935/abc.20150132.
[49] Masson VA, Monteiro MI. Life style, health aspects and 
work among truck drivers. Rev Bras Enferm 2010;63:533-40. 
doi: 10.1590/S0034-71672010000400006.
[50] Mieczkowski T. Urinalysis and hair analysis for illicit drugs of 
driver applicants and drivers in the trucking industry. J Forensic 
Leg Med 2010;17:254-60. doi: 10.1016/j.jflm.2010.02.014.
[51] Mir MU, Khan I, Ahmed B, Abdul Razzak J. Alcohol and mari-
juana use while driving - an unexpected crash risk in Pakistani 
commercial drivers: a cross-sectional survey. BMC Public Health 
2012;12:145. doi: 10.1186/1471-2458-12-145.
[52] Mongkolsirichaikul D, Mokkhavesa C, Ratanabanangkoon K. The 
incidence of amphetamine use among truck drivers from various 
regions of Thailand. J Med Assoc Thai 1988;71:471-4.
[53] Moreira RS, Gadani JAAB. A prevalência do uso de anfetaminas 
por caminhoneiros que passam pela cidade de Dourados-MS. In-
terbio 2009;3:27-34.
[54] Nascimento EC, Nascimento E, Silva JP. Uso de álcool e an-
fetaminas entre caminhoneiros de estrada. Rev Saúde Pública 
2007;41:290-3.
[55] Okpataku CI. Pattern and reasons for substance use among long-
distance commercial drivers in a Nigerian city. Indian J Public 
Health 2015;59:259-63. doi: 10.4103/0019-557X.169649.
[56] Peixe TS, de Almeida RM, Girotto E, de Andrade SM, Me-
sas  AE. Use of illicit drugs by truck drivers arriving at Para-
naguá port terminal, Brazil. Traffic Inj Prev 2014;15:673-7. 
doi: 10.1080/15389588.2013.868893.
[57] Penteado RZ, Gonçalves CGO, Costa DD, Marques JM. Trabalho 
e saúde em motoristas de caminhãono interior de São Paulo. Saúde 
Soc 2008;17:35-45.
[58] Pereira FGF, Aquino RA, Alencar VDM, Pordeus AMJ, Ataíde 
MBC. Relationship between work process and health of truckers. 
Rev Bras Promoç Saúde 2014;27:462-9.
[59] Pidetcha P, Congpuong P, Putriprawan T, Rekakanakul R, Suwan-
ton L, Tantrarongroj S. Screening for urinary amphetamine in truck 
drivers and drug addicts. J Med Assoc Thai 1995;78:554-8.
[60] Pinheiro MP, Muniz LF, Da Silva MCV, Resill DP, Filho PCPT. 
Amphetamines consumption and alcohol for truck drivers. J Nurs 
UFPE On Line Recife 2015;9:8519-25.
[61] Pinho RSN. Uso de estimulantes, queixa do sono e estado de 
humor em motoristas profissionais de caminhão. Dissertação 
(Mestrado em Ciências Farmacêuticas) - Universidade Federal 
do Ceará. Faculdade de Farmácia, Odontologia e Enfermagem, 
Fortaleza, 2005.
[62] Remor KVT, Monteiro MTM, Rosa VD, Iacovski RB, Sakae TM, 
Galato D. Abusive Consumption of psychoactive substances by 
truck drivers. Med Clin Rev 2015;2:1.
[63] Riva MM, Marchetti FA, Giupponi V, Mosconi G. Health surveil-
lance of truck drivers: it is not just a question of drugs. Description 
of a one-year experience. Med Lav 2010;101:207-17.
[64] Riva MM, Cantamessa F, Borleri D, Mosconi G. Occupational 
health and safety of road haulage company employees. Med Lav 
2018;109:180-9. doi: 10.23749/mdl.v109i3.6827.
[65] Sangaleti CT, Trincaus MR, Baratieri T, Zarowy K, Ladika MB, 
Menon MU, Miyahara RY, Raimondo MI, Silveira JV, Bortolotto 
LA, Lopes HF, Consolim-Colombo FM. Prevalence of cardiovas-
cular risk factors among truck drivers in the South of Brazil. BMC 
Public Health 2014;14:1063. doi: 10.1186/1471-2458-14-1063.
[66] Silva OA, Greve JMD, Yonamine M, Leyton V. Drug use by truck 
drivers in Brazil. Drug-Educ Prev Policy 2003;10:135-9. doi: org/1
0.1080/0968763021000057727.
[67] Sinagawa DM, De Carvalho HB, Andreuccetti G, Do Prado NV, 
De Oliveira KC, Yonamine M, Muñoz,DR, Gjerde H, Leyton V. 
Association between travel length and drug use among Brazilian 
truck drivers. Traffic Inj Prev 2015;16:5-9. doi: 10.1080/15389588
.2014.906589.
[68] Souza JC, Paiva T, Reimão R. Sleep habits, sleepiness and accidents 
among truck drivers. Arquivos de Neuro-Psiquiatria 2005;63:925-
30. doi: /S0004-282X2005000600004.
[69] Starmer GA, Mascord DJ, Tattam B, Zeleny R. Analysis for drugs 
in saliva. Canberra: Federal Office of Road Safety 1994, report 
No. CR141, 1-66.
[70] Takitane J, De Oliveira LG, Endo LG, De Oliveira KC, Muñoz 
DR, Yonamine M, Leyton V. Uso de anfetaminas por motoristas de 
caminhão em rodovias do Estado de São Paulo: um risco à ocorrên-
cia de acidentes de trânsito? Ciênc saúde coletiva 2013;18:1247-54.
[71] Teles AS, Matos MA, Caetano KAA, Cost LA, França DDS, Pes-
soni GC, Brunini SM, Martins RMB. Comportamentos de risco 
para doenças sexualmente transmissíveis em caminhoneiros no 
Brasil. Rev Panam Salud Publica 2008;24:25-30.
[72] Valway S, Jenison S, Keller N, Vega-Hernandez J, Hubbard Mc-
Cree D. Risk assessment and screening for sexually transmitted in-
fections, HIV, and hepatitis virus among long-distance truck drivers 
in New Mexico, 2004-2006. Am J Public Health 2009;99:2063-8. 
doi: 10.2105/AJPH.2008.145383.
[73] Williamson A. Predictors of psychostimulant use by long-distance 
truck drivers. Am J Epidemiol 2007;166:1320-6. doi: 10.1093/aje/
kwm205. 
[74] Yonamine M, Sanches LR, Paranhos BA, De Almeida RM, An-
dreuccetti G, Leyton V. Detecting alcohol and illicit drugs in oral 
#uid samples collected from truck drivers in the state of São Paulo, 
Brazil. Traf"c Inj Prev 2013;14:127-31. doi: 10.1080/15389588.20
12.696222.
[75] Sinagawa DM, De Carvalho HB, Andreuccetti G, Do Prado NV, 
De Oliveira KC, Yonamine M, Muñoz DR, Gjerde H, Leyton V. 
Association between travel length and drug use among Brazilian 
truck drivers. Traffic Inj Prev 2015;16:5-9. doi: 10.1080/15389588
.2014.906589.
[76] Knauth DR, Pilecco FB, Leal AF, Seffner F, Teixeira AM. Staying 
awake: truck drivers’ vulnerability in Rio Grande do Sul, Southern 
Brazil. Rev Saude Publica 2012;46:886-93.
[77] Kelly E, Darke S, Ross J. A review of drug use and driving: epide-
miology, impairment, risk factors and risk perceptions. Drug Alco-
hol Rev 2004;23:319-44. doi:  0.1080/09595230412331289482.
[78] Gustavsen I, Mørland J, Bramness JG. Impairment related to blood 
amphetamine and/or methamphetamine concentrations in suspect-
ed drugged drivers. Accid Anal Prev 2006;38:490-5. doi: 10.1016/j.
aap.2005.11.005.
[79] Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, 
Robertson MD, Swann P. The involvement of drugs in drivers of 
motor vehicles killed in Australian road traf"c crashes. Accid Anal 
Prev 2004;36:239-48.
[80] Musshoff F, Madea B. Driving under the influence of amphet-
amine-like drugs. J Forensic Sci 2012;57:413-9. doi: 10.1111/
j.1556-4029.2012.02055.
[81] Logan BK, Schwilke EW. Drug and alcohol use in fatally injured 
drivers in Washington State. J Forensic Sci 1996;41:505-10.
[82] Coambs RB, McAndrews MP. The Effects of psychoactive sub-
stances on workplace performance. In: Macdonald S, Roman P 
(eds.). Drug testing in the workplace. New York: Plenum Press 
1994, pp. 77-102.
[83] McKim W. Drugs and behavior. Cliffs, NJ: Prentice-Hall 1986.
PSYCHOACTIVE DRUG CONSUMPTION AMONG TRUCK-DRIVERS:  
A SYSTEMATIC REVIEW OF THE LITERATURE WITH META-ANALYSIS AND META-REGRESSION
E135
[84] Bolla K, Rothman R, Cadet JL. Dose-related neurobehavio-
ral effects of chronic cocaine use. J Neuropsych Clin Neurosci 
1999;11:361-9. doi: 10.1176/jnp.11.3.361.
[85] Burns M. Cocaine effects on performance. In: Utzelmann HD, 
Berghaus G, Kroj G (eds.). Alcohol, drugs, and traf"c safety-
T’92: proceedings of the 12th International Conference on Alco-
hol, Drugs and Traf"c Safety. Cologne: Verlag TUV Rheinland 
1993, pp. 612-9. 
[86] European Agency for Safety and Health at Work (EU-OSHA). A 
review on the future of work: performance-enhancing drugs. Avail-
able online: https://osha.europa.eu/sites/default/files/seminars/
documents/Performance%20enhancing%20drugs.pdf.
[87] Brookhuis KA, Volkerts ER, O’Hanlon JF. Repeated dose effects 
of lormetazepam and #urazepam upon driving performance. Eur J 
Clin Pharmacol 1990;39:83-7.
[88] Laurell H, Tornros J. The carry-over effects of triazolam compared 
with nitrazepam and placebo in acute emergency driving situations 
and in monotonous simulated driving. Acta Pharmacol Toxicol 
1986;58:182-6.
[89] O’Hanlon JF, Volkerts ER. Hypnotics and actual driving perfor-
mance. Acta Psychiatr Scand 1986;332:95-104.
[90] O’Hanlon JF, Haak TW, Blaauw GJ, Riemersma JB. Diazepam 
impairs lateral position control in highway driving. Science 
1982;217:79-81.
[91] Ramaekers JG, Robbe HWJ, O’Hanlon JJ. Marijuana. Human Psy-
chopharmacol 2000;15:551-8.
[92] Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk 
of injurious motor vehicle crashes in elderly drivers. Am J Epide-
miol 1992;136:873-83.
[93] Robbe HWJ. In#uence of marijuana on driving. CIP-Data 
Koninklinik Bibliothek. The Hague, Maastricht, The Nether-
lands: 1994
[94] Bondallaz P, Favrat B, Chtioui H, Fornari E, Maeder P, Gir-
oud C. Cannabis and its effects on driving skills. Forensic Sci Int 
2016;268:92-102. doi: 10.1016/j.forsciint.2016.09.007.
[95] Asbridge M, Hayden JA, Cartwright JL. Acute cannabis con-
sumption and motor vehicle collision risk: systematic review of 
observational studies and meta-analysis. BMJ 2012;344:e536. 
doi: 10.1136/bmj.e536.
[96] Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, 
Gorelick DA, Gaffney G, Huestis MA. Cannabis effects on driv-
ing longitudinal control with and without alcohol. J Appl Toxicol 
2016;36:1418-29. doi: 10.1002/jat.3295.
[97] Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gore-
lick DA, Gaffney G, Huestis MA. Cannabis effects on driving 
lateral control with and without alcohol. Drug Alcohol Depend 
2015;154:25-37. doi: 10.1016/j.drugalcdep.2015.06.015.
[98] Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-
Hamburger R, Cassuto Y, Shinar D. The effect of alcohol, THC 
and their combination on perceived effects, willingness to drive 
and performance of driving and non-driving tasks. Accid Anal Prev 
2010;42:1855-65. doi: 10.1016/j.aap.2010.05.006.
[99] Downey LA, King R, Papafotiou K, Swann P, Ogden E, Boor-
man M, Stough C. The effects of cannabis and alcohol on simu-
lated driving: influences of dose and experience. Accid Anal Prev 
2013;5:879-86. doi: 10.1016/j.aap.2012.07.016.
[100] Dubois S, Mullen N, Weaver B, Bédard M. The combined effects 
of alcohol and cannabis on driving: impact on crash risk. Forensic 
Sci Int 2015;248:94-100. doi: 10.1016/j.forsciint.2014.12.018.
[101] Goldsmith RS, Targin, MC, Fanciullo GJ, Martin DW, Harten-
baum NP, White JM, Franklin P. Medical marijuana in the work-
place: challenges and management options for occupational phy-
sicians. J Occup Environ Med 2015;57:518-25. doi:  10.1097/
JOM.0000000000000454.
[102] Strand MC, Vindenes V, Gjerde H, Mørland JG, Ramaekers JG. A 
clinical trial on the acute effects of methadone and buprenorphine 
on actual driving and cognitive function of healthy volunteers. Br J 
Clin Pharmacol 2019;85:442-53. doi: 10.1111/bcp.13818.
[103] Strand MC, Fjeld B, Arnestad M, Mørland J. Can patients receiv-
ing opioid maintenance therapy safely drive? A systematic review 
of epidemiological and experimental studies on driving ability with 
a focus on concomitant methadone or buprenorphine administra-
tion. Traffic Inj Prev 2013;14:26-38. doi: 10.1080/15389588.2012.
689451.
[104] Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opi-
oid-dependent/tolerant patients impaired in driving-related skills? 
A structured evidence-based review. J Pain Symptom Manage 
2003;25:559-77.
[105] Galski T, Williams JB, Ehle HT. Effects of opioids on driving abil-
ity. J Pain Symptom Manage 2000;19:200-8.
[106] Kaye AM, Kaye A, Lofton EC. Basic concepts in opioid prescrib-
ing and current concepts of opioid-mediated effects on driving. 
Ochsner J 2013;13:525-32.
[107] Wickens CM, Mann RE, Brands B, Ialomiteanu AR, Fischer B, 
Watson TM, Matheson J, Stoduto G, Rehm J. Driving under the 
influence of prescription opioids: self-reported prevalence and as-
sociation with collision risk in a large Canadian jurisdiction. Accid 
Anal Prev 2018;121:14-9. doi: 10.1016/j.aap.2018.08.026.
[108] Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnot-
ics and driving safety: meta-analyses of randomized controlled trials 
applying the on-the-road driving test. Curr Drug Saf 2006;1:63-71.
[109] Dubois S, Bédard M, Weaver B. The impact of benzodi-
azepines on safe driving. Traffic Inj Prev 2008;9:404-13. 
doi: 10.1080/15389580802161943.
[110] Van Laar MW, Volkerts ER. Driving and benzodiazepine use. Mol 
Diag Ther 1998;10:383. 
[111] Toennes SW, Kauert GF, Steinmeyer S, Moeller MR. Driving un-
der the influence of drugs - evaluation of analytical data of drugs in 
oral fluid, serum and urine, and correlation with impairment symp-
toms. Forensic Sci Int 2005;152:149-55. doi:  10.1016/j.forsci-
int.2004.08.002.
[112] Vindenes V, Lund HM, Andresen W, Gjerde H, Ikdahl SE, Christo-
phersen AS, Øiestad EL. Detection of drugs of abuse in simultane-
ously collected oral fluid, urine and blood from Norwegian drug 
drivers. Forensic Sci Int 2012;219:165-71. doi: 10.1016/j.forsci-
int.2012.01.001.
[113] Kelley-Baker T, Moore C, Lacey JH, Yao J. Comparing drug detec-
tion in oral fluid and blood: data from a national sample of night-
time drivers. Traffic Inj Prev 2014;15:111-8. doi: 10.1080/1538958
8.2013.796042.
[114] Casolin A. Comparison of urine and oral fluid for workplace drug 
testing. J Anal Toxicol 2016;40:479-85. doi: 10.1093/jat/bkw055.
[115] European Monitoring Centre for Drugs and Drug Addiction (EM-
CDDA). EU Action Plan on Drugs 2017-2020. Available online: 
www.emcdda.europa.eu/system/files/attachments/5642/eu-action-
plan%27-on-drugs-2017-2020.pdf.
[116] Carpenter CS. Workplace drug testing and worker drug use. 
Health Serv Res 2007;42:795-810. doi: 10.1111/j.1475-
6773.2006.00632.x.
Q Received on March 3, 2019. Accepted on April 2, 2019.
Q Correspondence: Nicola Luigi Bragazzi, Dipartimento di Scienze 
della Salute (DISSAL), Università degli Studi di Genova, l.go R. 
Benzi 10 (Padiglione 3), 16132 Genova, Italy - E-mail: dottornico-
laluigibragazzi@gmail.com
G. DINI ET AL.
E136
Supplementary material
Supplementary Fig. 1. Forest plots of amphetamine (A), cannabis (B), cocaine (C), opioids (D) and overall drug (E) use prevalence based 
on questionnaires. 
Supplementary Fig. 2. Meta-regression analysis of amphetamine use prevalence based on questionnaire, conducted for country as pa-
rameter. 
Supplementary Fig. 3. Meta-regression analysis of amphetamine use prevalence based on questionnaire, conducted for age as parameter.
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Supplementary Fig. 4. Meta-regression analysis of amphetamine use prevalence based on questionnaire, conducted for experience (in 
years) as parameter. 
Supplementary Fig. 5. Forest plots of amphetamine (A), cannabis (B), cocaine (C), opioids (D) and overall drug (E) use prevalence based 
on urine samples.
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Supplementary Fig. 6. Forest plots of amphetamine (A), cannabis (B), cocaine (C) and overall drug (D) use prevalence based on saliva 
samples.
Supplementary Fig. 7. Funnel plot of cannabis use prevalence based on saliva samples. showing evidence of publication bias. In white 
observed effect sizes, in black imputed effect sizes. 
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Supplementary Fig. 9. Funnel plot of overall drug use prevalence based on urine samples, showing evidence of publication bias. In white 
observed effect sizes, in black imputed effect sizes.
Supplementary Fig. 8. Funnel plot of over-the-counter stimulant use prevalence based on questionnaire, showing evidence of publica-
tion bias. In white observed effect sizes, in black imputed effect sizes. 
